We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
QNRX
826
Quoin Pharmaceuticals
QNRX
$8.59M
| $1.08M | ﹤0.01% |
+75,000
| New | +$1.02M |
|
827
Suzano
SUZ
$10.2B
| $1.06M | ﹤0.01% |
+113,099
| New | +$1.03M |
|
828
JD.com
JD
$43.5B
| $1.05M | ﹤0.01% |
36,681
-1,434
| -4% | -$44.8K |
|
829
Highwoods Properties
HIW
$3.79B
| $1.05M | ﹤0.01% |
40,666
+2,580
| +7% | +$72.8K |
|
830
LXP Industrial Trust
LXP
$3.52B
| $1.04M | ﹤0.01% |
20,904
-588
| -3% | -$28.2K |
|
831
Huntington Ingalls Industries
HII
$11B
| $999K | ﹤0.01% |
2,938
+716
| +32% | +$222K |
|
832
Graco
GGG
$13.2B
| $993K | ﹤0.01% |
12,113
+1,067
| +10% | +$87.8K |
|
833
Itaú Unibanco
ITUB
$89.8B
| $991K | ﹤0.01% |
138,383
+11,444
| +9% | +$81.4K |
|
834
Acadia Realty Trust
AKR
$3.11B
| $970K | ﹤0.01% |
47,227
+2,635
| +6% | +$52.5K |
|
835
Apple Hospitality REIT
APLE
$3.97B
| $950K | ﹤0.01% |
80,142
+4,275
| +6% | +$50.1K |
|
836
Yum China
YUMC
$15.7B
| $948K | ﹤0.01% |
19,861
-13,377
| -40% | -$613K |
|
837
Graphic Packaging
GPK
$3.35B
| $944K | ﹤0.01% |
62,689
-35,541
| -36% | -$584K |
|
838
Sigma Lithium
SGML
$1.05B
| $929K | ﹤0.01% |
70,465
-27,804
| -28% | -$240K |
|
839
TKO Group
TKO
$14B
| $926K | ﹤0.01% |
4,431
+651
| +17% | +$127K |
|
840
Bio-Techne
TECH
$11.2B
| $918K | ﹤0.01% |
15,613
+6,637
| +74% | +$403K |
|
841
Onto Innovation
ONTO
$10.9B
| $908K | ﹤0.01% |
5,749
-670
| -10% | -$95.2K |
|
|
LINE
842
Lineage Inc
LINE
$10.1B
| $894K | ﹤0.01% |
25,535
+1,427
| +6% | +$52.7K |
|
843
Universal Health Services
UHS
$10.2B
| $874K | ﹤0.01% |
4,011
-66
| -2% | -$14.6K |
|
844
Four Corners Property Trust
FCPT
$2.89B
| $874K | ﹤0.01% |
37,890
+5,048
| +15% | +$120K |
|
845
Urban Edge Properties
UE
$2.9B
| $874K | ﹤0.01% |
45,523
+3,897
| +9% | +$75.6K |
|
846
Nordson
NDSN
$16.4B
| $841K | ﹤0.01% |
3,498
| – | – |
|
847
Ralph Lauren
RL
$22.4B
| $801K | ﹤0.01% |
2,264
| – | – |
|
848
Shinhan Financial Group
SHG
$32.1B
| $761K | ﹤0.01% |
14,188
+3,627
| +34% | +$191K |
|
849
Akamai
AKAM
$15.6B
| $744K | ﹤0.01% |
8,530
-1,184
| -12% | -$97.4K |
|
|
WCN
850
Waste Connections
WCN
$43.6B
| $729K | ﹤0.01% |
4,155
-524
| -11% | -$90.6K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.